Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03466099 · ClinicalTrials.gov registry record · Phase 2
Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
A Phase 2 study of Diabetic Macular Edema, sponsored by KalVista Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
- 20
- Study locations
NCT03466099 is a Phase 2 study of Diabetic Macular Edema that has completed, run by KalVista Pharmaceuticals. The registered enrollment target is 129 participants, below the 3,792-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT03466099, a Phase 2 study of Diabetic Macular Edema, has completed, sponsored by KalVista Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a clinical study where patients with diabetes and a vision threatening eye condition called "Diabetic Macular Edema" receive four injections into the eye at monthly intervals. The patients will already have tried the standard of care without complete success. The patients will be randomized to receive either a high dose, a low dose or a sham control treatment. The study will evaluate whether the new treatment improves vision and whether it changes the underlying course of the disease in the eye.
Conditions Studied
Interventions
- OTHER Sham Procedure
- DRUG KVD001 Injection
Study Locations (20)
California
- KalVista Investigative Site - Arcadia
- KalVista Investigative Site - Beverly Hills
- KalVista Investigative Site - Palm Desert
- KalVista Investigative Site - Palo Alto
- KalVista Investigative Site - Sacramento
- KalVista Investigative Site - Santa Ana
- KalVista Investigative Site - Tustin
Florida
- KalVista Investigative Site - Fort Myers
- KalVista Investigative Site - Miami
- KalVista Investigative Site - Miami
- KalVista Investigative Site - Pensacola
- KalVista Investigative Site - Winter Haven
Arizona
- KalVista Investigative Site - Phoenix
- KalVista Investigative Site - Phoenix
- KalVista Investigative Site - Tucson
Georgia
- KalVista Investigative Site - Augusta
- KalVista Investigative Site - Marietta
Colorado
- KalVista Investigative Site - Golden
Indiana
- KalVista Investigative Site - Indianapolis
Massachusetts
- KalVista Investigative Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2018-02-16 |
| Est. Completion | 2019-10-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03466099
The ClinicalTrials.gov registry entry for NCT03466099 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,792-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (97% lower). The listed sponsor is KalVista Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Sham Procedure is the first listed.
NCT03466099 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03466099 about?
NCT03466099 is a clinical study titled "Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)". This is a clinical study where patients with diabetes and a vision threatening eye condition called "Diabetic Macular Edema" receive four injections into the eye at monthly intervals. The patients will already have tried the standard of care without complete success. The patients will be randomized ...
What is the current status of trial NCT03466099?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2018-02-16. Estimated completion is 2019-10-10.
What conditions does trial NCT03466099 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT03466099?
The interventions under investigation include: Sham Procedure (OTHER), KVD001 Injection (DRUG).
Who is sponsoring clinical trial NCT03466099?
This trial is sponsored by KalVista Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03466099 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
RECRUITING · Phase 2
-
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
ACTIVE NOT RECRUITING · Phase 2
-
4D-150 in Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Tonabersat for DME
ACTIVE NOT RECRUITING · Phase 2
-
Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.